行情

PIRS

PIRS

Pieris Pharms
NASDAQ

实时行情|Nasdaq Last Sale

5.43
-0.03
-0.55%
盘后: 5.43 0 0.00% 16:00 09/17 EDT
开盘
5.44
昨收
5.46
最高
5.62
最低
5.38
成交量
44.52万
成交额
--
52周最高
6.04
52周最低
2.390
市值
2.68亿
市盈率(TTM)
-7.0355
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PIRS 新闻

  • 日本8月出口连续9个月下滑 对华出口连降6个月
  • 新浪财经.4小时前
  • 世行行长:全球经济减速率超出估计
  • 新浪财经综合.4小时前
  • 新债王冈拉克:美债收益率已触底 别押注低利率
  • 新浪财经.4小时前
  • 美股地产股领涨能源股垫底 美联储降息概率进一步降低
  • 新浪科技.5小时前

更多

所属板块

生物技术和医学研究
+0.24%
制药与医学研究
+0.57%

热门股票

名称
价格
涨跌幅

PIRS 简况

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
展开

Webull提供Pieris Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。